Fresenius SE & Co. KGaA

Q2 organic revenue increased 6% year over year. EBIT increased 10% at constant currency, and group EBIT margin improved 60 basis points to 12.3%. Core EPS increased 14% at constant currency. Kabi organic revenue grew 7%, with growth vectors up 12% organic and Kabi EBIT margin at 17.9% (pharma EBIT margin 18.9% in the quarter). Helios organic revenue grew 5% and margin was 10.6%; Helios Germany organic revenue grew 6% and EBIT margin was 8.3%, while Helios Spain posted 3% organic revenue growth and a 14% EBIT margin. Operating cash flow in Q2 was EUR 344 million; LTM operating cash flow from continuing operations was EUR 2.8 billion and LTM free cash flow was EUR 1.6 billion. Leverage was 2.6x net debt-to-EBITDA. Guidance: full-year core EPS growth at constant currency is now 10% to 15%; Kabi EBIT margin is expected at the upper end of 16.5% to 17%; interest expense is now expected to be slightly below the prior year; if FX stayed at 30 June spot rates, management sees a slight positive impact of less than 1% on reported revenue, EBIT and net income for the full year.

Michael Sen framed the quarter as evidence that Fresenius has moved into a higher-quality, more resilient phase, with scaling growth vectors, better margins, higher returns and more financial flexibility. He emphasized that biopharma is becoming a meaningful earnings contributor, Helios is proving resilient, and the group now has multiple platforms that can compound over time. His tone was confident and strategic, but he repeatedly stressed discipline on capital allocation and that future deployment of capital will depend on opportunities and business needs.

Sara Hennicken focused on the hard financials and the operating leverage behind them: 6% organic revenue growth, 10% EBIT growth, 60 bps margin expansion to 12.3%, and 14% core EPS growth at constant currency. She highlighted strong cash generation, with Q2 operating cash flow of EUR 344 million, LTM operating cash flow of EUR 2.8 billion, LTM free cash flow of EUR 1.6 billion, and cash conversion of 1.2. She also noted leverage at 2.6x despite the dividend, a EUR 1 billion bond issuance in early July, and reiterated CapEx at around 5.5% of revenue, alongside commitment to an investment-grade balance sheet and 6% to 8% ROIC ambition.

Analysts pressed on why guidance was raised so materially, how H2 EPS could still vary widely, and whether Q4 would be a tougher comparison; management pointed to strong broad-based execution, continued Kabi momentum, biopharma launches, and normal seasonality, while noting Q4 is likely a harder comp. Questions on FMC centered on whether the stake should be monetized more aggressively; management said it remains a financial investment, not an operational asset, and any optionality is incremental. There were also questions on Helios Spain margin potential, Melrose Park FDA status, China nutrition VBP risk, and the durability of MedTech and biosimilar growth; management said the FDA site remains operational with no expected material 2026 impact, China is not expected to be a group growth driver, MedTech growth is being driven by Ivenix installations, and biosimilars remain a growth platform but will require continued investment and pipeline expansion.